Regulus Therapeutics (NASDAQ:RGLS) Earns Buy Rating from Canaccord Genuity Group

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating reaffirmed by stock analysts at Canaccord Genuity Group in a research note issued on Monday,Benzinga reports. They currently have a $28.00 price target on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research report on Friday, March 14th.

Regulus Therapeutics Stock Performance

Regulus Therapeutics stock opened at $1.38 on Monday. The company has a 50 day moving average price of $1.27 and a 200 day moving average price of $1.45. Regulus Therapeutics has a 52 week low of $0.83 and a 52 week high of $3.00. The firm has a market capitalization of $90.39 million, a price-to-earnings ratio of -1.29 and a beta of 1.42.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20). During the same quarter in the previous year, the company posted ($0.40) earnings per share. Equities analysts forecast that Regulus Therapeutics will post -0.88 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Crispina Calsada sold 38,716 shares of Regulus Therapeutics stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,782.16. Following the completion of the sale, the chief financial officer now owns 50,566 shares of the company’s stock, valued at approximately $63,713.16. The trade was a 43.36 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Joseph P. Hagan acquired 50,000 shares of Regulus Therapeutics stock in a transaction that occurred on Thursday, January 30th. The stock was acquired at an average cost of $1.09 per share, with a total value of $54,500.00. Following the purchase, the chief executive officer now owns 260,808 shares in the company, valued at $284,280.72. The trade was a 23.72 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 223,998 shares of company stock worth $282,237 in the last quarter. 4.35% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Regulus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC acquired a new stake in shares of Regulus Therapeutics in the 3rd quarter valued at $46,000. PEAK6 LLC acquired a new position in Regulus Therapeutics during the 4th quarter worth $95,000. Velan Capital Investment Management LP acquired a new position in Regulus Therapeutics during the 4th quarter worth $111,000. JPMorgan Chase & Co. lifted its position in Regulus Therapeutics by 193.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 52,059 shares during the last quarter. Finally, Barclays PLC lifted its position in Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 62,549 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.